Pharmaceutical company intelligence

P.D.H Pharmaceuticals (Pvt) Ltd

Private pharmaceutical manufacturer - P.D.H Group · Pakistan

P.D.H Group pharmaceutical manufacturing entity with a long-standing Pakistan healthcare legacy and established tablet and syrup manufacturing operations.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.

Official website ↗ Official contact ↗

Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details

Latest regulatory-source observation22 Sep 2026Newest linked source record observed by MedInfoBase

Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio

Latest effective price date27 Jul 2026Newest effective date among published current price records

Corporate profile evidence7 sourcesCorporate source details checked 21 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Location intelligence

Company location

Google Maps

Exact site not yet sourced

No exact premises location is published without a defensible source.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.

Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view

Rx52public portfolio records represented

REG49unique registrations represented

IDX6indexed MedInfoBase presentations

SRC0additional source-observed presentations

R+0registry-only registrations

VER0registry-verified exact registrations

PKR47current validated price records

G29generic molecules in indexed catalogue

DF7dosage-form groups

TA10therapeutic areas

How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage90%

public portfolio presentations with a validated current price

Official-source coverage100%

products linked back to a source record

Unit-price parse coverage98%

priced packs safely normalized per unit

Comparable-market coverage84%

products with at least one like-for-like comparator

Therapeutic classification100%

products assigned to a broad therapeutic area

Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives20 products · 41%

Cardiovascular6 products · 12%

CNS & mental health5 products · 10%

Ophthalmology5 products · 10%

Pain & musculoskeletal4 products · 8%

Fluids & supportive care3 products · 6%

Hematology & thrombosis2 products · 4%

Gastrointestinal & hepatology2 products · 4%

Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Fluoroquinolone antibacterials6 products · 12%

Analgesics / NSAIDs4 products · 8%

Glaucoma medicines4 products · 8%

Antipsychotics4 products · 8%

Other systemic antibacterials3 products · 6%

Fluids, electrolytes & diluents3 products · 6%

Antihypertensive medicines3 products · 6%

Oxazolidinone antibacterials3 products · 6%

Formulation footprint

Dosage forms

Tablet24 products

Suspension10 products

Drops8 products

Sachet3 products

Pessary2 products

Capsule1 products

Syrup1 products

How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales

#1 RisponRisperidone 4presentations 1 mg, 2 mg, 3 mg, 4 mg · Tablet #2 EndleatEnalapril 3presentations 10 mg, 20 mg, 5 mg · Tablet #3 OxalizidLinezolid 3presentations 100 mg/5 mL, 400 mg, 600 mg · Suspension, Tablet #4 FloracleanClotrimazole 2presentations 100 mg, 500 mg · Pessary #5 IbumidIbuprofen 2presentations 100 mg/5 mL, 600 mg · Suspension, Tablet #6 kuinkidCiprofloxacin 2presentations 125 mg/5 mL, 250 mg/5 mL · Suspension

Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis

Below market median3176% of comparable products

Near market median5within ±5% of median

Above market median512% of comparable products

Lowest-price equivalents8ties included

Company median price position -12.0% relative to the median unit price of like-for-like equivalent products.

Most competitively positioned examplesProducts with at least 3 market comparators

Endleat 20 mgEnalapril · Tablet · 2 x 10's PKR 19.22/tablet-48.5% vs market median Hynowell 7.5 mgMidazolam · Tablet · 10's PKR 6.83/tablet-39.9% vs market median Coagnor 5 mgWarfarin · Tablet · 10 x 10's PKR 8.03/tablet-36.1% vs market median kuinkid 250 mg/5 mLCiprofloxacin · Suspension · 60ml PKR 3.52/mL-32.0% vs market median Oxalizid 400 mgLinezolid · Tablet · 12's PKR 171.88/tablet-27.2% vs market median

How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

MS SIZA INTERNATIONAL PVT LTD.128 products · 63 generics 19shared generics Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 18shared generics Werrick Pharmaceuticals249 products · 82 generics 17shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.245 products · 97 generics 17shared generics Mediate Pharmaceutical Pvt Ltd236 products · 90 generics 16shared generics Valor Pharmaceuticals219 products · 97 generics 16shared generics

Regulatory & price activity

Observed database signals

Indexed registration numbers47Distinct registrations among indexed, published, presentation-validated products only

Verified price observations49

Products with a verified price48

Products with multiple price observations1

Source records with multiple versions48

Latest portfolio source check22 Sep 2026

Latest effective price date27 Jul 2026

Latest source observation22 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

49 unique registration(s) · 6 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Intelligence filter: Drug classFluoroquinolone antibacterials Clear intelligence filters

Brand	Generic	Strength	Form	Pack	Registration	Source-listed price	Unit price	Price position
Kuin	Ciprofloxacin	250 mg	Tablet	10's	030506	PKR 204.97	PKR 20.50/tablet	19% below median
kuinkid	Ciprofloxacin	125 mg/5 mL	Suspension	60ml	103636	PKR 215.59	PKR 3.59/mL	Near median
kuinkid	Ciprofloxacin	250 mg/5 mL	Suspension	60ml	103637	PKR 211.24	PKR 3.52/mL	32% below median
Kuinopt	Ciprofloxacin	3.5 mg/mL	Ophthalmic drops	5ml	025600	PKR 163.98	PKR 32.80/mL	No comparator
Quest	Levofloxacin	250 mg	Tablet	1 x 10's	029341	PKR 444.10	PKR 44.41/tablet	8% below median
Quest	Levofloxacin	500 mg	Tablet	1 x 10's	029342	PKR 717.39	PKR 71.74/tablet	9% below median

MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record

MedInfoBase. (2026). P.D.H Pharmaceuticals (Pvt) Ltd — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/p-d-h-pharmaceuticals-pvt-ltd/

Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.

P.D.H Pharmaceuticals (Pvt) Ltd

What is sourced, and how recent is it?

Company profile

Company location

Portfolio at a glance

How complete is this profile?

Downloadable company intelligence charts

Therapeutic Portfolio Mix

Dosage Form Portfolio

Equivalent Price Position

Closest Portfolio Competitors

Therapeutic areas

Drug classes

Dosage forms

Deepest brand families

Unit-price positioning vs equivalent products

Portfolio overlap

Observed database signals

Medicine portfolio

Cite this record